Arrowhead Pharmaceuticals Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period endedDecember31, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromtoCommission file number 001-38042_____________________________________ (I.R.S. Employer Identification No.) 177 E. Colorado Blvd, Suite 700Pasadena, California 91105(626) 304-3400(Address and telephone number of principal executive offices) Former name, former address, and former fiscal year, if changed since last report: N/A_____________________________________ Securities registered pursuant to Section 12(b) of the Exchange Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated FilerSmaller Reporting Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo PART I — FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS1Consolidated Balance Sheets1Consolidated Statements of Operations and Comprehensive Income (Loss)2Consolidated Statements of Stockholders’ Equity3Consolidated Statements of Cash Flows4Notes to Consolidated Financial Statements5ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS32ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK39ITEM 4. CONTROLS AND PROCEDURES39PART II — OTHER INFORMATION40ITEM 1. LEGAL PROCEEDINGS40ITEM 1A. RISK FACTORS40ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS40ITEM 3. DEFAULTS UPON SENIOR SECURITIES40ITEM 4. MINE SAFETY DISCLOSURES40ITEM 5. OTHER INFORMATION40ITEM 6. EXHIBITS41SIGNATURE42 Arrowhead Pharmaceuticals, Inc.Consolidated Balance Sheets(in thousands, except per share amounts) Arrowhead Pharmaceuticals, Inc.Consolidated Statements of Operations and Comprehensive Income (Loss)(in thousands, except per share amounts)(unaudited) Arrowhead Pharmaceuticals, Inc.Consolidated Statements of Stockholders’ Equity(in thousands)(unaudited) Arrowhead Pharmaceuticals, Inc.Consolidated Statements of Cash Flows(in thousands)(unaudited) Arrowhead Pharmaceuticals, Inc.Notes to Consolidated Financial Statements(unaudited) NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES General and Recent Developments Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the “Company”) are primarily engaged indeveloping medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries andefficient modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown oftarget genes. RNA interference (“RNAi”) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affectingthe production of a specific protein. The Company’s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target andshut down specific disease-causing genes. Approved Products REDEMPLO(plozasiran) is approved by the U.S. Food and Drug Administration (“FDA”) as an adjunct to diet to reduce triglyceridesfor adults with Familial Chylomicronemia Syndrome (“FCS”). REDEMPLO is also approved by the Chinese National Medical ProductsAdministration (NMPA). In addition, Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran) as anadjunct to diet to reduce triglycerides in adults with FCS for whom standard triglyceride lowering therapies have been inadequate.REDEMPLO is a small interfering RNA (“siRNA”) therapeutic designed to suppress the production of apolipoprotein C-III (APOC3), a proteinproduced in the liver that raises triglyceride levels by slo